(NASDAQ: MBRX) Moleculin Biotech's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.1%.
Moleculin Biotech's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast MBRX's revenue for 2026 to be $159,089,193, with the lowest MBRX revenue forecast at $159,089,193, and the highest MBRX revenue forecast at $159,089,193. On average, 1 Wall Street analysts forecast MBRX's revenue for 2027 to be $93,466,571, with the lowest MBRX revenue forecast at $93,466,571, and the highest MBRX revenue forecast at $93,466,571.
In 2028, MBRX is forecast to generate $193,816,167 in revenue, with the lowest revenue forecast at $193,816,167 and the highest revenue forecast at $193,816,167.